LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC raised its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 23.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,656 shares of the medical instruments supplier’s stock after purchasing an additional 6,320 shares during the quarter. Los Angeles Capital Management LLC owned about 0.15% of LeMaitre Vascular worth $3,126,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Conestoga Capital Advisors LLC increased its stake in shares of LeMaitre Vascular by 1.9% in the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after acquiring an additional 36,850 shares during the period. Vanguard Group Inc. grew its position in LeMaitre Vascular by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock worth $103,112,000 after purchasing an additional 4,964 shares during the period. Copeland Capital Management LLC lifted its holdings in shares of LeMaitre Vascular by 1.0% in the 3rd quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock valued at $108,068,000 after buying an additional 11,318 shares during the period. Congress Asset Management Co. boosted its stake in shares of LeMaitre Vascular by 2.6% in the third quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier’s stock worth $65,888,000 after buying an additional 18,295 shares during the last quarter. Finally, Driehaus Capital Management LLC grew its holdings in LeMaitre Vascular by 52.2% during the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after acquiring an additional 90,573 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Down 2.1 %

LeMaitre Vascular stock opened at $103.26 on Wednesday. The stock has a market cap of $2.32 billion, a P/E ratio of 56.79, a PEG ratio of 2.55 and a beta of 0.89. The company has a 50-day moving average price of $90.96 and a 200 day moving average price of $84.86. LeMaitre Vascular, Inc. has a 12-month low of $48.66 and a 12-month high of $106.49.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm’s quarterly revenue was up 15.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.33 earnings per share. As a group, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be issued a $0.16 dividend. The ex-dividend date of this dividend is Thursday, November 21st. This represents a $0.64 annualized dividend and a yield of 0.62%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 34.97%.

Wall Street Analyst Weigh In

LMAT has been the topic of several recent research reports. JMP Securities upped their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Barrington Research raised their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Oppenheimer reissued an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Wednesday, November 6th. Finally, Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.